The potential of psychedelic medicine - A personal account.
Journal of the neurological sciences – March 15, 2022
Source: PubMed
Summary
Psychedelics were once explored as therapeutic drugs before criminalization halted research. A toxicologist, living in Haight Ashbury in 1965, studied compounds like LSD, observing their early use for conditions such as addiction. Despite initial promise, negative publicity led to Schedule 1 classification, suppressing exploration of these entheogens and entactogens. This historical account suggests a significant, untapped potential for recovery, highlighting how early therapeutic applications were sidelined.
Abstract
In 1965, I was training in clinical toxicology in the pharmacology department of the University of California San Francisco (UCSF) and living in the Haight Ashbury. I studied various psychedelics, including LSD, mescaline, and ibogaine, in human and animal models. The psychedelics were then being used as a therapeutic drug in clinical settings and researched as a potential antipersonnel agent by the U.S. government. Then, using psychedelics became a rite of passage for the emerging countercultural movement. After adverse reactions and negative publicity, states began to criminalize these drugs, beginning in 1966. The federal government eventually moved these drugs to Schedule 1 classification, shutting down research almost entirely.